Study drug for advanced solid tumors with RET changes
Part of Cancer clinical trials.
This early-stage study tests a new drug (HEC169096) in people with advanced solid tumors that cannot be removed by surgery. It focuses on tumors with specific RET gene changes, aiming to control or shrink the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid cancer that cannot be removed with surgery (non-resectable).
- Your tumor test shows an RET gene change (RET fusion/rearrangement or mutation that is not a silent or non-working change).
- Your health and daily functioning are good enough (ECOG 0–2).
- You can have blood and organ tests within safe ranges (bone marrow, liver, and kidneys).
- You can provide tumor tissue (archived tumor sample or a new biopsy) for testing.
- You’re able to take part for at least 12 weeks and, if you can get pregnant, you have a negative pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called HC006 for advanced solid tumors that no longer respond to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
This Phase 1 trial tests a new medicine (HG381) in people with advanced solid tumors to see how safe it is and how it works in the body. It may help if standard treatments have already stopped working or aren’t possible for you.
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
This trial studies a new drug called HW071021 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can help shrink or control the cancer.
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.